N4 Pharma PLC Holding(s) in Company (4315T)
20 Marzo 2019 - 3:40AM
UK Regulatory
TIDMN4P
RNS Number : 4315T
N4 Pharma PLC
20 March 2019
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the N4 Pharma Plc
underlying issuer of existing shares
to which voting rights are attached(ii)
:
--------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify)(iii) :
----
3. Details of person subject to the notification obligation(iv)
Name First Equity Limited
City and country of registered office London, UK
(if applicable)
4. Full name of shareholder(s) (if different from 3.)(v)
Name Disclosure on behalf of accounts
managed on a discretionary basis
by First Equity Limited
--------------------------------------------
City and country of registered office
(if applicable)
--------------------------------------------
5. Date on which the threshold was 19 March 2019
crossed or reached(vi) :
--------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 20 March 2019
--------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer(vii)
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ --------------------- -------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 3.45% 3.45% 101,462,537
------------------ --------------------- -------------- --------------------
Position of NA NA
previous notification
(if
applicable)
------------------ --------------------- -------------- --------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached(viii)
A: Voting rights attached to shares
Class/type of Number of voting rights(ix) % of voting rights
shares
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) Directive 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
-----------------------------------
GB00BYW8QM32 3,500,000 3.45%
------------------------------ ----------------------------------- ------------------------ -----------------------
SUBTOTAL 8. A 3,500,000 3.45%
------------------------------------------------------------------- -------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date(x) Conversion Period(xi) rights that may rights
be acquired if
the instrument
is
exercised/converted.
----------------- --------------------------------------- --------------------------------- -----------------------
SUBTOTAL 8. B 1
--------------------------------------- --------------------------------- -----------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date(x) Conversion cash voting rights rights
instrument Period (xi) settlement(xii)
----------------------------- ------------------------ ----------------------------- -----------------
SUBTOTAL 8.B.2
----------------------------- -----------------
9. Information in relation to the person subject to the notification obligation
(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any X
natural person or legal entity and does not control any other undertaking(s)
holding directly or indirectly an interest in the (underlying) issuer(xiii)
Full chain of controlled undertakings through which the voting rights
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity(xiv) (please add additional
rows as necessary)
Name(xv) % of voting rights % of voting rights Total of both
if it equals or through financial if it equals or
is higher than the instruments if it is higher than
notifiable threshold equals or is higher the notifiable
than the notifiable threshold
threshold
-------------------------------------------- --------------------------------- -------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
------------------------------------------------------------
The number and % of voting rights held
------------------------------------------------------------
The date until which the voting rights
will be held
------------------------------------------------------------
11. Additional information(xvi)
Place of completion London
Date of completion 20 March 2019
--------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
HOLLIFVAVVIIFIA
(END) Dow Jones Newswires
March 20, 2019 05:40 ET (09:40 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
